

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.:201843233N
(Incorporated in the Republic of Singapore)

UPDATE ON TRAINING REQUIREMENT FOR FIRST TIME DIRECTOR

The Board of Directors (“**Board**”) of Singapore Paincare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcement released on 05 March 2021 in respect of the appointment of Dr. Lim Kah Meng (“**Dr. Lim**”) as the Independent Non-Executive Director of the Company.

Pursuant to Practice Note 4D of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”), a director who has no prior experience as a director of a listing applicant listed on the SGX-ST must undergo training in the roles and responsibilities of a director of a listed issuer as prescribed by the SGX-ST (the “**Prescribed Training**”) within one year from the date of his appointment to the Board.

The Board wishes to update that Dr. Lim was unable to undergo the Prescribed Training conducted by the Singapore Institute of Directors (“**SID**”) as required within the prescribed timeline under Practice Note 4D of the Catalist Rules by 04 March 2022 due to conflicts between the earlier available dates / timing and his work commitments as well as having been diagnosed with COVID-19. Notwithstanding the foregoing, it is noted that the next availability of the SID courses are scheduled to be in May, June and July 2022. Accordingly, Dr. Lim has registered himself for the SID courses, being LED1 to LED8 and the training on sustainability matters to be held in May, June and July 2022. Further, Dr. Lim has confirmed his commitment to complete his Prescribed Training by July 2022.

By Order of the Board
Lee Mun Kam Bernard
Executive Director and Chief Executive Officer
08 April 2022

Singapore Paincare Holdings Limited (the “**Company**”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 30 July 2020. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the “**Sponsor**”).

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.